神戸大学附属図書館デジタルアーカイブ
入力補助
English
カテゴリ
学内刊行物
ランキング
アクセスランキング
ダウンロードランキング
https://hdl.handle.net/20.500.14094/90007231
このアイテムのアクセス数:
54
件
(
2024-09-27
09:15 集計
)
閲覧可能ファイル
ファイル
フォーマット
サイズ
閲覧回数
説明
90007231 (fulltext)
pdf
6.30 MB
12
メタデータ
ファイル出力
メタデータID
90007231
アクセス権
open access
出版タイプ
Version of Record
タイトル
Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
著者
Nishimura, Meiko ; Hayashi, Mitsuhiro ; Mizutani, Yu ; Takenaka, Kei ; Imamura, Yoshinori ; Chayahara, Naoko ; Toyoda, Masanori ; Kiyota, Naomi ; Mukohara, Toru ; Aikawa, Hiroaki ; Fujiwara, Yasuhiro ; Hamada, Akinobu ; Minami, Hironobu
著者名
Nishimura, Meiko
著者名
Hayashi, Mitsuhiro
著者名
Mizutani, Yu
著者名
Takenaka, Kei
著者ID
A2078
研究者ID
1000080796160
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=faae382bacd342f9520e17560c007669
著者名
Imamura, Yoshinori
今村, 善宣
イマムラ, ヨシノリ
所属機関名
医学部附属病院
著者名
Chayahara, Naoko
著者名
Toyoda, Masanori
著者ID
A1407
研究者ID
1000040515037
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=5fd898ae58a689e3520e17560c007669
著者名
Kiyota, Naomi
清田, 尚臣
キヨタ, ナオミ
所属機関名
医学部附属病院
著者名
Mukohara, Toru
著者名
Aikawa, Hiroaki
著者名
Fujiwara, Yasuhiro
著者名
Hamada, Akinobu
著者ID
A1398
研究者ID
1000060450574
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=29f74a5e8b26a0a9520e17560c007669
著者名
Minami, Hironobu
南, 博信
ミナミ, ヒロノブ
所属機関名
医学研究科
言語
English (英語)
収録物名
Oncotarget
巻(号)
9(26)
ページ
18540-18547
出版者
Impact Journals
刊行日
2018-04-06
公開日
2020-07-15
抄録
Background: The development of skin rashes is the most common adverse event observed in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such as erlotinib. However, the pharmacological evidence has not been fully revealed. Results: Erlotinib distribution in the rashes was more heterogeneous than that in the normal skin, and the rashes contained statistically higher concentrations of erlotinib than adjacent normal skin in the superficial skin layer (229 ± 192 vs. 120 ± 103 ions/mm2; P = 0.009 in paired t-test). LC-MS/MS confirmed that the concentration of erlotinib in the skin rashes was higher than that in normal skin in the superficial skin layer (1946 ± 1258 vs. 1174 ± 662 ng/cm3; P = 0.028 in paired t-test). The results of MALDI-MSI and LC-MS/MS were well correlated (coefficient of correlation 0.879, P < 0.0001). Conclusions: Focal distribution of erlotinib in the skin tissue was visualized using non-labeled MALDI-MSI. Erlotinib concentration in the superficial layer of the skin rashes was higher than that in the adjacent normal skin. Methods: We examined patients with advanced pancreatic cancer who developed skin rashes after treatment with erlotinib and gemcitabine. We biopsied both the rash and adjacent normal skin tissues, and visualized and compared the distribution of erlotinib within the skin using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). The tissue concentration of erlotinib was also measured by liquid chromatography-tandem mass spectrometry (LC–MS/MS) with laser microdissection.
キーワード
erlotinib
rash
mass spectrometry imaging
drug distribution
liquid chromatography-tandem mass spectrometry
カテゴリ
医学研究科
医学部附属病院
学術雑誌論文
権利
© Nishimura et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
関連情報
DOI
https://doi.org/10.18632/oncotarget.24928
詳細を表示
資源タイプ
journal article
eISSN
1949-2553
OPACで所蔵を検索
CiNiiで学外所蔵を検索
ホームへ戻る